MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after ...

Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic ...

Agreement expands offering to include additional sheet, particulate and flowable productsMARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) ...

The company raised its full year 2025 revenue growth outlook from the low teens to the mid- to high teens and now expects the full year adjusted EBITDA margin to be at least in the mid-20s as a ...

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event. MIMEDX is a pioneer and leader focused on helping ...

MiMedx Group Inc. (MDXG) shares gained around 5% in Wednesday morning’s trade after the company entered into an exclusive distribution agreement with Summit Products Group for three of its 510(k) ...

Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific PublicationsMARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or ...

The average one-year price target for MiMedx Group (NasdaqCM:MDXG) has been revised to $10.61 / share. This is a decrease of 14.75% from the prior estimate of $12.44 dated January 11, 2026. The price ...

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held ...

MiMedx Group admitted to no wrongdoing but agreed to pay $6.5 million to resolve a case in which the company was charged with knowingly giving false pricing information to the U.S. Department of ...

MiMedx Group Inc MDXG is trading significantly lower Monday after the company announced top-line results from two late-stage musculoskeletal clinical trials. Top-line results from an interim analysis ...